<table id="table13" width="95%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13: Drug Interactions: Changes in Pharmacokinetic Parameters for Nelfinavir in the Presence of the Coadministered Drug</caption>
<col align="left" span="1" valign="top" width="20%"></col>
<col align="left" span="1" valign="top" width="25%"></col>
<col align="center" span="1" valign="top" width="10%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<col align="center" span="1" valign="top" width="15%"></col>
<tbody>
<tr>
<th colspan="1"></th>
<th colspan="1"></th>
<th colspan="1"></th>
<th colspan="3">% Change of Nelfinavir Pharmacokinetic Parameters<linkhtml href="#footnote-7">*</linkhtml> (90% CI)</th>
</tr>
<tr>
<th colspan="1">Coadministered Drug</th>
<th colspan="1">Nelfinavir Dose</th>
<th colspan="1">N</th>
<th colspan="1">AUC</th>
<th colspan="1">C<sub>max</sub>
</th>
<th colspan="1">C<sub>min</sub>
</th>
</tr>
<tr>
<td>
<content stylecode="bold">HIV-Protease Inhibitors</content>
</td>
</tr>
<tr>
<td>Indinavir 800 mg q8h × 7 days</td>
<td>750 mg Single Dose</td>
<td>6</td>
<td>↑83%<br/>(↑42–↑137%)</td>
<td>↑31%<br/>(↑16–↑48%)</td>
<td>NA</td>
</tr>
<tr>
<td>Ritonavir 500 mg q12h × 3 doses</td>
<td>750 mg Single Dose</td>
<td>10</td>
<td>↑152%<br/>(↑96–↑224%)</td>
<td>↑44%<br/>(↑28–↑63%)</td>
<td>NA</td>
</tr>
<tr>
<td>Saquinavir 1200 mg TID × 4 days<linkhtml href="#footnote-8">†</linkhtml>
</td>
<td>750 mg Single Dose</td>
<td>14</td>
<td>↑18%<br/>(↑7–↑30%)</td>
<td>↔</td>
<td>NA</td>
</tr>
<tr>
<td>
<content stylecode="bold">Nucleoside Reverse Transcriptase Inhibitors</content>
</td>
</tr>
<tr>
<td>Didanosine 200 mg Single Dose</td>
<td>750 mg Single Dose</td>
<td>9</td>
<td>↔</td>
<td>↔</td>
<td>NA</td>
</tr>
<tr>
<td>Zidovudine 200 mg + Lamivudine 150 mg Single Dose</td>
<td>750 mg q8h × 7–10 days</td>
<td>11</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>
<content stylecode="bold">Non-nucleoside Reverse Transcriptase Inhibitors</content>
</td>
</tr>
<tr>
<td>Efavirenz 600 mg qd × 7 days</td>
<td>750 mg q8h × 7 days</td>
<td>7</td>
<td>↑20%<br/>(↑8–↑34%)</td>
<td>↑21%<br/>(↑10–↑33%)</td>
<td>↔</td>
</tr>
<tr>
<td>Nevirapine 200 mg qd × 14 days followed by 200 mg BID × 14 days</td>
<td>750 mg TID × 36 days</td>
<td>23</td>
<td>↔</td>
<td>↔</td>
<td>↓32%<br/>(↓50–↑5%)</td>
</tr>
<tr>
<td>Delavirdine 400 mg q8h × 7 days</td>
<td>750 mg q8h × 14 days</td>
<td>12</td>
<td>↑107%<br/>(↑83–↑135%)</td>
<td>↑88%<br/>(↑66–↑113%)</td>
<td>↑136%<br/>(↑103–↑175%)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Anti-infective Agents</content>
</td>
</tr>
<tr>
<td>Ketoconazole 400 mg qd × 7 days</td>
<td>500 mg q8h × 5–6 days</td>
<td>12</td>
<td>↑35%<br/>(↑24–↑46%)</td>
<td>↑25%<br/>(↑11–↑40%)</td>
<td>↑14%<br/>(↓23–↑69%)</td>
</tr>
<tr>
<td>Rifabutin 150 mg qd × 8 days</td>
<td>750 mg q8h × 7–8 days</td>
<td>11</td>
<td>↓23%<br/>(↓14–↓31%)</td>
<td>↓18%<br/>(↓8–↓27%)</td>
<td>↓25%<br/>(↓8–↓39%)</td>
</tr>
<tr>
<td></td>
<td>1250 mg q12h × 7–8 days</td>
<td>11</td>
<td>↔</td>
<td>↔</td>
<td>↓15%<br/>(↓43–↑27%)</td>
</tr>
<tr>
<td>Rifabutin 300 mg qd × 8 days</td>
<td>750 mg q8h × 7–8 days</td>
<td>10</td>
<td>↓32%<br/>(↓15–↓46%)</td>
<td>↓24%<br/>(↓10–↓36%)</td>
<td>↓53%<br/>(↓15–↓73%)</td>
</tr>
<tr>
<td>Rifampin 600 mg qd × 7 days</td>
<td>750 mg q8h × 5–6 days</td>
<td>12</td>
<td>↓83%<br/>(↓79–↓86%)</td>
<td>↓76%<br/>(↓69–↓82%)</td>
<td>↓92%<br/>(↓86–↓95%)</td>
</tr>
<tr>
<td>Azithromycin 1200 mg Single Dose</td>
<td>750 mg tid × 9 days</td>
<td>12</td>
<td>↓15%<br/>(↓7–↓22%)</td>
<td>↓10%<br/>(↓19–↑1%)</td>
<td>↓29%<br/>(↓19–↓38%)</td>
</tr>
<tr>
<td>
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr>
<td>Phenytoin 300 mg qd × 7 days</td>
<td>1250 mg BID × 14 days</td>
<td>15</td>
<td>↔</td>
<td>↔</td>
<td>↓18%<br/>(↓45–↑23%)</td>
</tr>
<tr>
<td>Omeprazole 40 mg qd × 4 days administered 30 minutes before nelfinavir</td>
<td>1250 mg BID × 4 days</td>
<td>19</td>
<td>↓36%<br/>(↓20–↓49%)</td>
<td>↓37%<br/>(↓23–↓49%)</td>
<td>↓39%<br/>(↓15–↓57%)</td>
</tr>
</tbody>
</table>